About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristant #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Snatching Defeat from the Jaws of Victory? | Main | USPTO Asks out of Gene Patenting Case (Again) »

January 18, 2010

Comments

Kevin,

Why doesn't it surprise that those who oppose 12-year data exclusivity for biosimilars can't get their facts straight as to when that period starts?

Many have noted the Democrats' proclivity for snatching defeat from the jaws of victory; but who would have anticipated that this would extend even to the realm of patent law? I would not have predicted that the politics of patent law could in fact doom much-needed health-care legislation. But the recent upset in Massachusetts presents that distinct possibility.
http://www.GeneralPatent.com

The comments to this entry are closed.

August 2019

Sun Mon Tue Wed Thu Fri Sat
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31